Last reviewed · How we verify
Prasugrel Oral Tablet
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation and thrombosis.
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation and thrombosis. Used for Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI).
At a glance
| Generic name | Prasugrel Oral Tablet |
|---|---|
| Also known as | Effient, effient |
| Sponsor | Elliot Israel, MD |
| Drug class | P2Y12 receptor antagonist (thienopyridine) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Prasugrel is a prodrug that is metabolized to an active thiol metabolite, which then binds irreversibly to the P2Y12 receptor on platelet surfaces. This prevents adenosine diphosphate (ADP)-induced platelet activation and aggregation. By blocking this key pathway in platelet function, prasugrel reduces the risk of thrombotic cardiovascular events.
Approved indications
- Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI)
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Rash
Key clinical trials
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects (PHASE1)
- Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia (PHASE4)
- Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. (PHASE4)
- Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) (PHASE4)
- CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI (PHASE4)
- Prasugrel in Severe COVID-19 Pneumonia (PHASE3)
- Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis (PHASE3)
- Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prasugrel Oral Tablet CI brief — competitive landscape report
- Prasugrel Oral Tablet updates RSS · CI watch RSS
- Elliot Israel, MD portfolio CI